Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Abstract Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor...

Full description

Bibliographic Details
Main Authors: Ana Fernández Montes, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Francisca Vázquez Rivera, Nieves Martinez Lago, Marta Covela Rúa, Antía Cousillas Castiñeiras, Paula Gonzalez Villarroel, Juan De la Cámara Gómez, José Carlos Méndez Méndez, Carmen Carriles Fernández, Manuel Sanchez Cánovas, Teresa Garcia García
Format: Article
Language:English
Published: Nature Portfolio 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-93732-5

Internet

https://doi.org/10.1038/s41598-021-93732-5

Similar Items